A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
The first signs of the disease are different for children. It might start after a child has a nerve disorder called acute disseminated encephalomyelitis (ADEM). Most of the time, the symptoms of ADEM -- including headache, confusion, coma, seizures, stiff neck, fever, and major lack of energy -- go away after a few weeks. But some children will keep having problems that are the same as MS.
Multiple sclerosis may get worse more slowly in children than in adults. But people who had the condition in childhood or adolescence can have physical disability at an earlier age. The disease also may cause greater challenges with thinking and emotions for children and teens, and may affect their schoolwork, self-image, and relationships with peers.
MS Symptoms in Children
The symptoms are similar to those in adults and may include:
It’s natural to want to do anything you can to help tame your multiple sclerosis symptoms. You take your medicine and keep up with your doctor visits. Would it also make a difference to change what you eat?
Although no diet is proven to give you relief, some nutrients may make a difference for better or worse.
There is no such thing as a special “MS diet” that has been proven to improve symptoms. Most doctors recommend you eat a low-fat, high-fiber diet similar to the one recommended for the general public by major medical organizations.
Go for a variety of fruits and vegetables, whole grains, low-fat dairy products, skinless poultry and fish, nuts, and legumes. Avoid items that are highly processed and high in saturated fat.
Gluten-Free May Not Help
Ditching gluten is popular, and for people who have celiac disease, it’s a must. But no research shows that it improves MS symptoms.
Several studies have found that people with MS aren’t more likely than anyone else to be sensitive to gluten. So if you decide to go gluten-free, MS probably is not the reason to do so.
NEW YORK: Taking a high dose of vitamin D could be an inexpensive and easy way to treat people with multiple sclerosis (MS), an autoimmune disorder that affects the brain and spinal chord, suggests promising new research.
"These results are exciting, as vitamin D has the potential to be an inexpensive, safe and convenient treatment for people with multiple sclerosis," said study author Peter Calabresi from Johns Hopkins University School of Medicine in the US.
Low levels of vitamin D in the blood are tied to an increased risk of developing MS and are more likely to have greater disability and more disease activity.
The current recommended daily allowance of vitamin D is 600 international units.
For the study, 40 people with relapsing-remitting MS received either 10,400 international units or 800 international units of vitamin D supplements per day for six months.
Patients with severe vitamin D deficiency were not included in the study.
Blood tests at the start of the study and again at three and six months measured the amount of vitamin D in the blood and the response in the immune system's T cells, which play a key role in MS.
Sperm-associated antigen 16 (SPAG16), a sperm protein which is upregulated in reactive astrocytes in multiple sclerosis (MS) lesions, has recently been identified as a novel autoantibody target in MS. The aim of this study was to investigate whether anti-SPAG16 antibody levels differ between MS subtypes (relapsing-remitting, RR; primary or secondary progressive, PP, SP) and whether antibody positivity is associated with clinical characteristics.
Plasma anti-SPAG16 antibody levels were determined by recombinant protein enzyme-linked immunosorbent assay (ELISA) in 374 MS patients (274 RRMS, 39 SPMS and 61 PPMS) and 106 healthy controls.
Significantly elevated anti-SPAG16 antibodies were found in 22% of MS patients with 93% specificity. Anti-SPAG16 seropositivity was associated with an increased Expanded Disability Status Scale (EDSS) in overall MS. A higher proportion of PPMS patients showed anti-SPAG16 antibody reactivity (34%) compared to RRMS (19%) and SPMS (26%), and presented with higher anti-SPAG16 antibody levels. Seropositive PPMS patients had a significantly increased progression index compared to seronegative patients.
MS is a debilitating disease in which cells of the immune system attack the central nervous system (CNS), namely nerve fibers and myelin, the element that covers and protects nerve cells. The symptoms and severity of MS vary greatly from patient to patient, although functional limitations such as walking/gait dysfunction and balance impairment are fairly common. Walking difficulties arise from factors such as muscle weakness, spasticity (muscle tightness), balance problems, sensory deficits, and fatigue.
Dalfampridine in extended release (ER) form (Ampyra extended-release tablets; Acorda Therapeutics Inc.) has been shown to rehabilitate conduction in demyelinated nerves in animals. Data from two Phase 3 clinical trials showing that dalfampridine-ER was able to improve walking speed in MS patients was key to its being granted approval in the United States in 2010.
As some of you may have learned from
correspondence received from CVS/Caremark, effective January 1, 2016,
PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a) will be
excluded from a subset of CVS/Caremark commercial health insurance plans. This
change will NOT impact all patients who have CVS/Caremark health insurance.
Therapy decisions are best left to be
determined by patients and their physicians. There are actions that patients
and their physicians can take to ensure that they can remain on their current
therapy. Individuals impacted by CVS/Caremark’s decision can work with
their physicians as follows:
The physician can submit
a medical exception/letter of medical necessity directly to CVS/Caremark
If the medical exception
letter is not successful, an appeal can be filed
During the appeal
process, the patient may be eligible to receive interim doses from Biogen
to ensure there is no disruption in treatment
the appeal is denied, patients may be eligible for Biogen’s patient
Patients that need
assistance in understanding and navigating their health insurance coverage
can contact Biogen Support Coordinators at 1-800-456-2255; M-F, 8:30am –
Through the support program, Biogen is
committed to helping patients and provides support services to patients
and caregivers, such as financial and insurance support, nurse educators,
support coordination, and peer connections
There are reports suggesting that people with Klinefelter’s syndrome (KS) may be at increased
risk of some autoimmune diseases, but the evidence is not substantial. We wanted to add to
the evidence by systematically assessing the risk of autoimmune diseases in a national cohort
of people with KS. We selected records of all people with KS in a record-linked dataset of all
hospital day cases and inpatient admissions in England, 1999–2011; and we followed them up
by electronic record linkage to identify the occurrence of autoimmune diseases.
their occurrence in the KS cohort with a control cohort, studied in the same way, and expressed
the results as rate ratios (RR). Of 30 autoimmune diseases studied in people with KS, there
were significantly increased risks of seven–Addison’s disease (RR 11.7, 95% confidence interval
2.4–34.4), diabetes mellitus type 1 (6.1, 4.4–8.3), multiple sclerosis (4.3, 1.2–11.0), acquired
hypothyroidism (2.7, 1.8–4.0), rheumatoid arthritis (3.3, 2.0–5.2), Sjogren’s syndrome (19.3,
4.0–57.0) and systemic lupus erythematosus (18.1, 2.2–65.6). We concluded that people with KS
have increased risk of some autoimmune diseases, particularly those that are femalepredominant.
The increased risk of autoimmune diseases associated with the XXY karyotype
may hold clues to the pathogenesis of some aspects of autoimmunity